Natera (NTRA) –
-
Form 4 Natera, Inc. For: Apr 15 Filed by: Chapman Steven Leonard
-
Form 4 Natera, Inc. For: Apr 16 Filed by: Moshkevich Solomon
-
Form 144 Natera, Inc. Filed by: Moshkevich Solomon
-
Form 144 Natera, Inc. Filed by: Chapman Steven Leonard
-
Natera (NTRA) PT Raised to $100 at Goldman Sachs
-
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
-
Craig-Hallum Assumes Natera (NTRA) at Buy
-
Natera (NTRA) Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
-
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
-
Natera (NTRA) call put ratio 3.5 calls to 1 put as share price up 5.1%
-
Natera (NTRA) Reports Positive Surveillance Analysis from Phase III IMvigor011 Trial
-
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
-
Bernstein SocGen Group Upgrades Natera (NTRA) to Outperform
-
Form 4 Natera, Inc. For: Apr 02 Filed by: Brophy Michael Burkes
-
Form 4 Natera, Inc. For: Apr 03 Filed by: Sheena Jonathan
-
Form 144 Natera, Inc. Filed by: Sheena Jonathan
-
Form 144 Natera, Inc. Filed by: Brophy Michael Burkes
-
Cabot Wealth shares top 10 stocks picks for this week
-
Natera (NTRA) and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103
-
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
-
Form 4 Natera, Inc. For: Mar 28 Filed by: Moshkevich Solomon
-
Form 4 Natera, Inc. For: Mar 27 Filed by: Sheena Jonathan
-
Form 4 Natera, Inc. For: Mar 28 Filed by: Fesko John
-
Form 4 Natera, Inc. For: Mar 27 Filed by: RABINOWITZ DANIEL
-
Form 4 Natera, Inc. For: Mar 15 Filed by: Chapman Steven Leonard
-
Form 4 Natera, Inc. For: Mar 27 Filed by: Brophy Michael Burkes
-
Form 144 Natera, Inc. Filed by: Sheena Jonathan
-
Natera (NTRA) announces phase III trial of signatera to treat stage II colorectal cancer in France
-
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
-
Form 4 Natera, Inc. For: Mar 15 Filed by: BOTHA ROELOF
-
Form 4 Natera, Inc. For: Mar 15 Filed by: Chapman Steven Leonard
-
Form 144 Natera, Inc. Filed by: Chapman Steven Leonard
-
Form 144 Natera, Inc. Filed by: Chapman Steven Leonard
-
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
-
Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
-
Form 4 Natera, Inc. For: Mar 07 Filed by: Sheena Jonathan
-
Form 4 Natera, Inc. For: Mar 05 Filed by: Brophy Michael Burkes
-
Form 4 Natera, Inc. For: Mar 05 Filed by: Rabinowitz Matthew
-
Form 4 Natera, Inc. For: Mar 05 Filed by: Chapman Steven Leonard
-
Form 4 Natera, Inc. For: Mar 05 Filed by: RABINOWITZ DANIEL
-
Form 4 Natera, Inc. For: Feb 29 Filed by: Moshkevich Solomon
-
Form 4 Natera, Inc. For: Feb 29 Filed by: Fesko John
-
Form 4 Natera, Inc. For: Mar 05 Filed by: Sheena Jonathan
-
Natera (NTRA) Announces Commercial Coverage for Prospera Kidney and Prospera Heart from a Top BCBS Plan
-
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
-
Natera (NTRA) PT Raised to $110 at Piper Sandler
-
Form 144 Natera, Inc. Filed by: Rabinowitz Matthew
-
Form 4 Natera, Inc. For: Feb 29 Filed by: Sheena Jonathan
-
Form 4 Natera, Inc. For: Mar 01 Filed by: Moshkevich Solomon
-
Form 4 Natera, Inc. For: Mar 01 Filed by: Chapman Steven Leonard
Back to NTRA Stock Lookup
